University of Bergen, Haukeland University Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dietz, Andreas
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
ELOS, NCT06137378: European Larynx Organ Preservation Study () [MK-3475-C44]

Recruiting
2
140
Europe
KEYTRUDA®, Pembrolizumab, MK-3475
University of Leipzig, University of Göttingen, University of Jena, University of Cologne, University of Ulm, University of Regensburg, Wuerzburg University Hospital, Technical University of Munich, Ernst von Bergmann Hospital, Universitätsmedizin Mannheim, University of Kiel
Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV, Laryngeal Squamous Cell Carcinoma, Laryngectomy; Status, Laryngeal Cancer, Laryngeal Neoplasms
12/28
12/30
ADRISK, NCT03480672 / 2017-002546-74: Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
240
Europe
Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA], adjuvant radiochemotherapy
University of Leipzig
HNSCC
01/25
01/25
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
HNC-TACTIC, NCT05117775: Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. .

Recruiting
N/A
10000
Europe
No intervention - Just description and predictive models
Savana Research, Head and Neck Cancer International Group (HNCIG)
Head and Neck Cancer
02/24
12/24
Hitre, Erika
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
FEEL, NCT04675528: Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) Study

Completed
1
25
Europe
DHP107(Oral paclitaxel), Liporaxel®
Daehwa Pharmaceutical Co., Ltd.
Advanced Solid Tumor
12/22
12/22
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing
N/A
Europe, Canada, US, RoW
Olaratumab, LY3012207
Eli Lilly and Company
Soft Tissue Sarcoma
 
 
Brydoy, Marianne
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28

Download Options